Introduction
============

Mycotoxins are small compounds produced by fungi with specific moisture and temperatures, and pose a threat to animal and human health \[[@B8],[@B19]\]. Zearalenone (ZEN) is produced by *Fusarium* (*F.*) fungi including *F. graminearum*, *F. culmorum*, *F. equiseti*, *F. cerealis*, *F. crookwellense*, and *F. semiectum* \[[@B2]\]. This toxin is heat-stable and found in maize, barley, oats, wheat, rice, and bread. ZEN is a potent estrogenic metabolite which causes reproductive problems, such as infertility and abortion \[[@B10]\], in animals that consume cereals contaminated with the toxin. The most susceptible animal is swine \[[@B13]\]. Aflatoxin is produced by *Aspergillus* (*A.*) *flavus* and *A. parasiticus*, and exists as four major types: B1, B2, G1, and G2 \[[@B14],[@B23]\]. Hazardous effects of this toxin have been well documented. In particular, aflatoxin B1 (AFB1) is an extremely potent liver carcinogen \[[@B14]\].

Detection and surveillance of mycotoxins is highly important for preventing animals and/or humans from consuming grain products contaminated with these compounds. Recent regulations regarding AFB1 and ZEN were implemented to minimize health problems caused by the toxins although the maximum permissible toxin levels differ among countries \[[@B24]\]. Several methods have been employed to monitor toxin levels in grain products including thin-layer chromatography \[[@B11]\], gas chromatography.mass spectrometry \[[@B16]\], high-performance liquid chromatography (HPLC) \[[@B11],[@B17],[@B20]\], and enzyme-linked immunosorbent assays \[[@B11],[@B18]\]. When identifying official methods for monitoring purposes, purification efficacy for mycotoxin testing is critical because it ensures accuracy and precision when determining the level of mycotoxin contamination. The use of immunoaffinity columns (IACs) with monoclonal antibodies (mAbs) is currently the most popular method for purifying mycotoxin contaminants from samples \[[@B3],[@B17],[@B20]\]. However, this method is expensive, time-consuming, and produces inconsistent results, which makes it impractical.

Nanoparticles are substances that have recently been used for various applications such as the treatment of disease, drug delivery, and diagnostics \[[@B4],[@B9],[@B15]\]. Recent studies have indicated the usefulness of nanoparticles for recovering heavy metals from water and isolating harmful microbes from livestock products \[[@B6],[@B7],[@B21]\]. The purpose of the current study was to develop an advanced purification tool for isolating mycotoxins by utilizing mAbs and magnetic nanoparticles (MNPs). We hypothesized that this technique would facilitate purification by magnetism and combine high capacity for purification with fast dispersibility due to the small size of the particles.

Materials and Methods
=====================

mAbs and MNPs
-------------

mAbs (kj-AFB against AFB1 and kk-ZEN against ZEN) were produced in our laboratory and shown to have greater specificity and affinity than commercial mAbs ([Fig. 1](#F1){ref-type="fig"}). MNPs (*fluidMAG*-MNPs) with five different functional groups \[*fluidMAG*-amine (fMA), *fluidMAG*-carboxyl, (fMC), *fluidMAG*-protein A/G (fMA/fMG), *fluidMAG*-streptavidin (fMS)\] used in this study were purchased from Chemicell (Germany; [Table 1](#T1){ref-type="table"}). *fluidMAG*-MNPs are ferrofluids consisting of an aqueous dispersion of magnetic iron oxides (Fe~2~O~3~) with diameters of 100 nm and 200 nm. The particles are covered with hydrophilic polymers that protect against aggregation promoted by foreign ions. Terminal functional groups such as ion-exchange groups or reactive groups for covalent immobilization can be used for binding to biomolecules.

MNP coupling to mAbs
--------------------

The five types of MNPs were activated before being coupled to mAbs following the manufacturer\'s protocols. Briefly, 2 mg of an fMA suspension was washed three times using a magnet in coupling buffer (0.01 M pyridine, pH 6.0). A glutaraldehyde solution (5%, 1 mL) was added and incubated with the MNPs at room temperature for 30 min. The particles were washed with wash buffer (0.01 M Tris, 0.15 M NaCl; and 0.1% BSA, pH 7.4) by magnetic separation ([Fig. 2](#F2){ref-type="fig"}). mAb coupling was conducted by dissolving 50, 100, and 200 µg of each mAb (kj-AFB or kk-ZEN) in 550 µL of coupling buffer and incubated with the activated magnetic particles for 16 to 24 h at room temperature ([Fig. 2](#F2){ref-type="fig"}). The MNP.mAb conjugates (fMA-AFB1 and fMA-ZEN) were washed and stored in the wash buffer at 4℃ before use.

fMC particles were prepared by adding 2 mg of particle suspension to 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-*p*-toluenesulfonate (CMC) and incubating at room temperature. After incubation, the particles were washed with distilled and deionized water. The particles were then incubated with 100 µg of mAb diluted in phosphate buffered saline (PBS). The MNP-mAb conjugates (fMC-AFB1 and fMC-ZEN) were maintained in storage buffer (PBS, 0.1% BSA, and 0.05% sodium azide) at 4℃.

The fMA/fMG particles were prepared by resuspending 2 mg of the MNP suspension in binding buffer (0.1 M sodium phosphate and 0.15 M NaCl, pH 7.5) and washing by magnetic separation. The washed MNPs were coupled with mAbs diluted in PBS at room temperature. The mAb-conjugated MNPs (fMA/fMG-AFB1 and fMA/fMG-ZEN) were stored at 4℃ in PBS containing 0.02% sodium azide.

fMS particles were prepared by washing 2 mg of the particle suspension with PBS by magnetic separation. The particles were coupled with biotinylated mAbs at room temperature. The mAb-coupled MNPs (fMS-AFB1 and fMS-ZEN) were then washed with PBS and stored at 4℃.

Extraction of mycotoxins from feed
----------------------------------

Five g of feed samples \[corn and mixed grains (product X) without detectable level of mycotoxins in our test condition\] were purchased from a feed company in Korea. The feed samples were ground and spiked with 10 ppb AFB1 and 50 ppb ZEN. After vigorous shaking, mycotoxins were extracted by incubation for 3 min in 70% methanol. The extracted samples were passed through Whatman No. 1 filter paper; 10 mL of the filtrate was mixed with 40 mL of PBS (pH 7.4) and used for mycotoxin purification trials in this study.

Mycotoxin purification using mAb-coupled MNPs and IACs
------------------------------------------------------

To purify the mycotoxins, MNP-mAb conjugates were mixed with 5 mL of the processed samples (50 mL) or 5 mL PBS containing mycotoxins for 5 min at room temperature with shaking. After the reaction, MNP-mAb conjugates bound to the mycotoxins were magnetically removed from the supernatant, which was discarded. The mycotoxins were dissociated from the MNP-mAbs by adding 500 µL of 100% methanol and gently shaking. After dissociation, the MNP-mAb particles were magnetically removed perpendicular to gravity, and mycotoxin concentrations in the samples were measured.

IAC-AFB1 (NeoColumn; Neogen, USA) and IAC-ZEN (Easi-extract zearalenone; R-Biopharm, Germany) were used to isolate AFB1 and ZEN, respectively, and the mycotoxins were purified following the manufacturer\'s protocol. Briefly, the columns were washed with 20 mL PBS by gravity at a flow rate of 5 mL/min. Next, 50 mL of the extracted samples were passed through the washed columns by gravity. The mycotoxins were eluted with 100% methanol and used for HPLC analysis.

HPLC analysis of the eluted mycotoxins
--------------------------------------

Mycotoxins purified by MNP-mAb conjugates or IACs were analyzed by HPLC using a Symmetry C18 column (Waters, USA) for ZEN and an X teorra RP18 column (Waters, USA) for AFB1. The analytical column was equilibrated with water-acetonitrile (50 : 50, v : v) at a flow rate 1 mL/min. The eluted sample (10 µL) was injected into the HPLC system (Waters, USA). Using a fluorescence detector (Waters, USA), sample analysis was conducted at an excitation wavelength of 274 nm and emission wavelength of 440 nm for ZEN, and 365 nm (excitation) and 480 nm (emission) for AFB1.

Data analysis
-------------

Mean recovery rates were analyzed using a one-way ANOVA test. Differences between the two purification methods were compared using Student\'s *t*-test (JMP ver. 6.0; SAS, USA). Graphs were prepared using SigmaPlot (ver. 8.0; Systat Software, USA).

Results
=======

Selection of MNPs suitable for mAb coupling
-------------------------------------------

Ten MNPs (diameters of 100 nm and 200 nm) with five different functional groups were chosen and coupling efficiency with mAbs (kk-ZEN) against ZEN was tested. As shown in [Fig. 3](#F3){ref-type="fig"}, 100 µg of mAb were coupled with 2 mg of MNPs (100-nm diameter). It was found that an average of 96.7% and 63.3% of mAbs were bound to fMA and fMS, respectively. In contrast, less than 8% of the mAbs were bound to the MNPs conjugated to the other functional groups (fMC and fMA/fMG). There was no significant effect associated with MNP size because particles with a 200-nm diameter produced similar results (data not shown). fMA particles with a 100-nm diameter were therefore used for the subsequent studies.

Establishment of optimal mAb coupling conditions for the selected MNPs and evaluation of purification capacity of the MNP-mAb conjugates
----------------------------------------------------------------------------------------------------------------------------------------

Two mg of fMA particles were incubated with mAbs at three different concentrations (50, 100, and 200 µg) in PBS to determine the optimal concentration of mAbs for MNP coupling. The mycotoxin purification capacity of the MNP-mAb conjugates (fMA-AFB1 and fMA-ZEN) produced with each mAb concentration was also evaluated by incubating 500 µg of the conjugates with 10 ng AFB1 and 50 ng ZEN in PBS, respectively. It was found that kj-AFB1 was increasingly coupled to fMA in a mAb concentration-dependent manner: 17.03 ± 0.76 µg (50 µg), 42.31 ± 2.28 µg (100 µg), and 94.30 ± 3.78 µg (200 µg) per 1 mg of MNPs. However, the purification capacity of fMA-AFB1 declined in a manner inversely proportional to the amount of mAb bound to the MNP: 1.21 ± 0.03 ng (50 µg), 1.07 ± 0.13 ng (100 µg), 0.63 ± 0.09 ng (200 µg) per 1 µg of mAb on fMA-AFB1 complex. A similar observation was made in the coupling test evaluating kk-ZEN coupled to fMA particles: 15.27 ± 0.32 µg (50 µg), 40.25 ± 0.73 µg (100 µg), 96.66 ± 2.96 µg (200 µg) per 1 mg of MNP. In contrast, the ZEN purification capacity declined sharply: 2.56 ± 0.11 ng (50 µg), 2.26 ± 0.08 ng (100 µg), 1.76 ± 0.09 ng (200 µg) per 1 µg of mAb on the fMA-ZEN complex ([Fig. 4](#F4){ref-type="fig"}).

Mycotoxin purification efficiency from feed by MNP-mAb conjugates and comparison with IACs
------------------------------------------------------------------------------------------

The limit of detection and maximum quantities of mycotoxins purified using fMA-AFB1 (1 mg) or fMA-ZEN (1 mg) were measured with 2 mg fMA and 100 µg mAb (0.1 ng/mL and 45.3 ng/mL for AFB1, respectively, and 2 ng/mL and 90.9 ng/mL for ZEN, respectively). Thus, fMA-AFB1 (1 mg) and fMA-ZEN (1 mg) were used to evaluate recovery rates and comparison with the IAC recovery rates. The average recovery rates of the fMA-AFB1 and fMA-ZEN conjugates were compared with those of IAC-AFB1 and IAC-ZEN by testing corn and product X feed samples spiked with AFB1 (5, 10, and 15 ng) or ZEN (10, 25, and 50 ng). As shown in [Fig. 5](#F5){ref-type="fig"}, recovery rates for fMA-AFB1 (90\~92% and 81\~88%) were higher (*p* \> 0.05) than those for IAC-AFB1 (81\~84% and 72\~78%), while the rates for fMA-ZEN (99\~100% and 92\~94%) were significantly (*p* \< 0.01) higher than those of IAC-ZEN (86\~88% and 81\~88%) except for 10 ng/mL ZEN in product X. The coefficients of variation (CV) for fMA-AFB1 and IAC-AFB1 associated with the three different mycotoxin concentrations were 1.11\~1.22% and 5.97\~9.16% for corn feed, respectively, and 2.23\~2.65% and 10.6\~15.56% for product X, respectively. On the other hand, the CV for fMA-ZEN and IAC-ZEN were 3.24\~3.77% and 4.89\~6.57% for corn, respectively, and 3.42\~3.93% and 7.84\~9.78% for product X, respectively ([Table 2](#T2){ref-type="table"}).

Discussion
==========

This study is the first report of an animal feed mycotoxin purification system using MNPs. The use of nanoparticles for purifying target molecules such as heavy metals \[[@B22]\] and bacteria \[[@B5]\] has been explored because of particle dispersibility and cost effectiveness of this procedure. Thus, feasible applications in new areas have been discovered. Mycotoxins are a threat to public health because these compounds contaminate cereals and a variety of grains consumed by humans and animals \[[@B12]\]. The current study explored the possible use of MNPs for mycotoxin purification by coupling the particles to mAbs specific for mycotoxins. This was done to find a suitable replacement for current purification methods.

The mAb coupling efficiencies of commercially produced MNPs (100-nm and 200-nm diameters) were tested. The functional groups on the MNPs were capable of binding mAbs through diverse mechanisms. For example, an amine group covalently binds to the carboxyl group of the mAbs whereas the carboxyl group covalently binds to the mAb amine group. Protein A/G binds the Fc portion of mAbs, and streptavidin is specific for biotin molecules on biotinylated mAbs. In our selection tests, MNPs with an amine functional group were found to be the most appropriate for the current study.

The selected MNP (fMA) was used to test MNP-antibody coupling capacity, and mycotoxin purification capacity of the MNP-mAb conjugates was evaluated. Antibodies coupled with the MNPs in an antibody concentration-dependent manner. However, the mycotoxin purification capacity declined as the amount of antibody coupled to the MNPs increased. The surface of nanoparticles has a limited area available for coupling, so it is possible that excess antibody \[[@B1]\] on the MNP surface (7.5 nm in length) might hamper the antibody-antigen reaction due to steric hindrance.

IAC-based techniques are currently the most popular method for purifying mycotoxins from feeds \[[@B11],[@B16]\]. However, this method is expensive, time-consuming, and requires the application of a large volume of solvent, which makes it a tedious process. In the present study, mycotoxin purification efficiency and procedure feasibility of the MNP-mAb conjugates was compared with that of IACs. Each commercial IAC was manufactured to purify more than 100 ng of mycotoxin while the MNP-mAb conjugates (fMA-AFB1 and fMA-ZEN) had the capacity to purify approximately 45.3 ng of AFB1 or 90.9 ng of ZEN. Comparison of the two methods showed that the MNP-mAb conjugates had a significantly (*p* \< 0.01) higher recovery rate and lower CV values compared to the IACs. There could be two possible reasons for the observation. First, the mAbs used in our study were made in the laboratory, and had a demonstrably higher affinity and specificity for toxins compared to commercially available antibodies (data not shown). Second, prolonged washing with large amounts of washing buffer during the IAC procedure might result in a loss of toxins bound to the antibody in the column. Our new method used MNP-mAb conjugates that separate toxins from unbound materials using magnetism. The washing process is also very fast, simple, and uses only a small amount of buffer. Furthermore, our novel method required only approximately 5 min to complete (from antibody binding to elution) whereas the IAC-based procedure took longer than 30 min. More importantly, the amount of mycotoxin purified using our method was more consistent and reproducible compared to the IACs as indicated by the lower CV values (CV value of the MNP-mAb conjugates was less than 4.0 in contrast to 4.8 for the IACs), suggesting that our novel method is more reliable than IACs.

In summary, we developed a new mycotoxin purification method using nanoparticles that exhibited remarkable efficiency. Our findings suggested that this method could replace IAC techniques that are widely used for separating mycotoxins from feed.
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![Competitive ELISA for measuring mAb specificity and affinity of (A) kj-AFB and (B) kk-ZEN. The mAbs we developed (kj-AFB or kk-ZEN) or commercial mAbs \[C\] at different dilutions (1/250, 1/500, and 1/1,000 for C; 1/64, 1/128, 1/256, 1/512, and 1/1024 for kk-ZEN; 1/16, 1/32, 1/64, 1/128, and 1/256 for kj-AFB). kj-AFB and kk-ZEN were found to have greater specificity as well as affinity than the commercial mAbs.](jvs-13-363-g001){#F1}

![Separation of MNPs using a magnet.](jvs-13-363-g002){#F2}

![Coupling efficiency of MNPs with a diameter of 100 nm. MNPs (2 mg) were coupled with 100 µg of the kk-ZEN mAb specific for ZEN (n = 3). The amount of bound mAb is presented as the mean ± SE. ^\*^*p* \< 0.01.](jvs-13-363-g003){#F3}

![Optimal coupling conditions with different concentration of mAbs and the mycotoxin purification capacity. MNPs (2 mg) were coupled with 50, 100, or 200 µg of mAbs (n = 3) and 1 mg each *fluidMAG-amine* (fMA)-AFB1 (A) and fMA-ZEN (B). All values were significantly different (*p* \< 0.01) except for differences in the amounts of mycotoxin purified by MNPs coupled with 50 µg or 100 µg of AFB1-specific mAb. ^\*^Indicates the mean ± SE.](jvs-13-363-g004){#F4}

![Comparison of recovery rates for the MNP-mAb conjugates (fMA-AFB1 and fMA-ZEN) and immunoaffinity columns (IAC-AFB1 and IAC-ZEN) from corn (A) or product X (B) feed samples (n = 3). Recovery rate (%) = (amount of purified mycotoxins/amount of spiked mycotoxins) × 100. ^\*^*p* \< 0.01.](jvs-13-363-g005){#F5}
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Magnetic nanoparticles (MNPs) used in the current study
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Comparison of coefficients of variation (CV) between the MNP-based and immunoaffinity columns (IACs) for purifying mycotoxins from corn and product X feed
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^\*^CV (%) indicates the coefficient of variation as a percentage (n = 3). CV (%) = (SD/mean) × 100. fMA: *fluidMAG-amine*.
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